-
公开(公告)号:PE20100054A1
公开(公告)日:2010-03-03
申请号:PE2009000770
申请日:2009-06-03
Applicant: ABBOTT LAB
Inventor: GHAYUR TARIQ , HAHN ALFRED , MUELLER BERNHARD
Abstract: REFERIDA A UNA PROTEINA DE UNION QUE COMPRENDE UNA CADENA POLIPEPTIDICA VD1-(X1)n-VD2-C-(X2)n, DONDE VD1 ES UN PRIMER DOMINIO VARIABLE DE CADENA PRESADA Y VD2 ES UN SEGUNDO DOMINIO VARIABLE DE CADENA PESADA QUE COMPRENDEN UNA SECUENCIA DE AMINOACIDOS SELECCIONADA DE SEQ ID NO: 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54 Y 56; C ES UN DOMINIO CONSTANTE DE LA CADENA PESADA; X1 ES UN CONECTOR, CON LA CONDICION DE QUE NO SEA CH1; X2 ES UNA REGION Fc DE SECUENCIA VARIANTE; n ES 0 O 1. TAMBIEN ESTA REFERIDA A UN VECTOR, UNA CELULA HUESPED, UN PROCEDIMIENTO DE PREPARACION Y UNA COMPOSICION FARMACEUTICA. DICHA PROTEINA DE UNION ES UTIL EN EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS AGUDAS Y CRONICAS, CANCER, ENTRE OTRAS
-
公开(公告)号:PE18452009A1
公开(公告)日:2010-01-08
申请号:PE0005782009
申请日:2009-04-29
Applicant: ABBOTT LAB
Inventor: GHAYUR TARIQ , MORGAN-LAPPE SUSAN E , REILLY EDWARD B , KINGSBURY GILLIAN A , PHILLIPS ANDREW , WANG JIEYI , BELL RANDY L , NORVELL SUZANNE M , LI YINGCHUN , LIU JUNJIAN , YING HUA
IPC: G01N33/53
CPC classification number: C07K16/468 , A61K39/39533 , A61K45/06 , A61K2039/505 , C07K16/22 , C07K16/28 , C07K16/2863 , C07K16/32 , C07K2317/31 , C07K2317/565 , C07K2317/64 , C07K2317/71 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/92 , C07K2319/00 , G01N33/6872 , G01N33/74 , G01N2333/515 , G01N2333/705 , Y02A50/386 , Y02A50/41 , Y02A50/412 , Y02A50/58 , Y10S435/81
Abstract: SE REFIERE A UNA PROTEINA DE UNION QUE COMPRENDE: A) UNA PRIMERA CADENA DE POLIPEPTIDOS QUE COMPRENDE: VD1-(X1)n-VD2-C-(X2)n DONDE VD1 Y VD2 SON UN PRIMER Y SEGUNDO DOMINIO VARIABLE DE CADENA PESADA QUE COMPRENDEN UNA SECUENCIA DE AMINOACIDOS TAL COMO SEQ ID Nº 27, SEQ ID Nº 29, SEQ ID Nº 31, SEQ ID Nº 33, ENTRE OTROS; C ES UN DOMINIO CONSTANTE DE LA CADENA PESADA; (X1)n ES UN CONECTOR, QUE NO ES CH1; (X2)n ES UNA REGION Fc DE UNA IgG1, IgG2, IgG3, ENTRE OTROS, CUYA SECUENCIA DE AMINOACIDOS SE SELECCIONA DE LA SEQ ID Nº 1-26; Y B) UNA SEGUNDA CADENA DE POLIPEPTIDOS QUE COMPRENDE: VD1-(X1)n-VD2-C-(X2)n DONDE VD1 Y VD2 SON UN PRIMER Y SEGUNDO DOMINIO VARIABLE DE CADENA LIVIANA QUE COMPRENDEN UNA SECUENCIA DE AMINOACIDOS TAL COMO SEQ ID Nº 28, SEQ ID Nº 30, SEQ ID Nº 32, SEQ ID Nº 34, ENTRE OTROS; C ES UN DOMINIO CONSTANTE DE LA CADENA LIVIANA; (X1)n ES UN CONECTOR, QUE NO ES CH1; (X2)n ES UNA REGION Fc DE UNA IgG1, IgG2, IgG3, ENTRE OTROS, CUYA SECUENCIA DE AMINOACIDOS SE SELECCIONA DE LA SEQ ID Nº 1-26; DONDE DICHOS VD1 Y VD2 DE CADENA PESADA Y DE CADENA LIVIANA SE OBTIENEN DE UN PRIMER Y SEGUNDO ANTICUERPO PARENTAL RESPECTIVAMENTE O DE UNA PORCION DE UNION AL ANTIGENO DEL MISMO. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE OBTENCION DE UN DOMINIO VARIABLE DUAL DE INMUNOGLOBULINA CAPAZ DE UNIRSE A DOS ANTIGENOS TALES COMO CD20 Y CD19, EGFR Y HER-2, EGFR Y c-MET, ENTRE OTROS
-
公开(公告)号:CA2725666A1
公开(公告)日:2009-12-10
申请号:CA2725666
申请日:2009-06-03
Applicant: ABBOTT LAB
Inventor: GHAYUR TARIQ , HAHN ALFRED , MUELLER BERNHARD
Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
-
公开(公告)号:AU2009256246A1
公开(公告)日:2009-12-10
申请号:AU2009256246
申请日:2009-06-03
Applicant: ABBOTT LAB
Inventor: MUELLER BERNHARD , GHAYUR TARIQ , HAHN ALFRED
-
公开(公告)号:BRPI0615026A2
公开(公告)日:2009-06-16
申请号:BRPI0615026
申请日:2006-08-18
Applicant: ABBOTT LAB
Inventor: WU CHENGBIN , GHAYUR TARIQ , DIXON RICHARD W , SALFELD JOCHEN G
Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases.
-
126.
公开(公告)号:MX2009005361A
公开(公告)日:2009-06-05
申请号:MX2009005361
申请日:2007-11-21
Applicant: ABBOTT LAB
Inventor: MEZLER MARIO , MOELLER ACHIM , MUELLER REINHOLD , MUELLER BERNHARD K , GHAYUR TARIQ , BARLOW EVE H , SCHMIDT MARTIN , MEYER AXEL , TEUSCH NICOLE
IPC: A61K39/395
Abstract: El tema de la invención se relaciona con proteínas aisladas particularmente anticuerpos monoclonales, los cuales se unen con el receptor de Nogo-66. Específicamente, los anticuerpos tienen la capacidad de inhibir la unión del ligando natural del receptor de Nogo-66 y neutralizar el receptor de Nogo-66. Estos anticuerpos o porciones de los mismos de la invención son útiles par detectar NgR y para inhibir la actividad de NgR, por ejemplo, en un ser humano que padece un trastorno en el que la actividad de NgR o Nogo-66 es perjudicial.
-
公开(公告)号:AU2008322595A1
公开(公告)日:2009-05-22
申请号:AU2008322595
申请日:2008-11-14
Applicant: ABBOTT LAB
Inventor: BARDWELL PHILIP , GHAYUR TARIQ
IPC: A61K31/496 , A61K31/635 , A61P19/02
-
公开(公告)号:CA2805859A1
公开(公告)日:2005-05-26
申请号:CA2805859
申请日:2004-11-12
Applicant: ABBOTT LAB
Inventor: GHAYUR TARIQ , LABKOVSKY BORIS , VOSS JEFFREY W , GREEN LARRY , BABCOOK JOHN , JIA XIAO-CHI , WIELER JAMES , KANG JASPAL SINGH , HEDBERG BRAD
Abstract: The present invention encompasses IL-18 binding proteins, particularly antibodies that bind human interleukin-18 (hIL-18). Specifically, the invention relates to antibodies that are entirely human antibodies. Preferred antibodies have high affinity for hIL-18 and/or that neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.
-
公开(公告)号:AU2004290073A1
公开(公告)日:2005-05-26
申请号:AU2004290073
申请日:2004-11-12
Applicant: ABBOTT LAB
Inventor: JIA XIAO-CHI , WIELER JAMES , GREEN LARRY , HEDBERG BRAD , LABKOVSKY BORIS , BABCOOK JOHN , KANG JASPAL SINGH , VOSS JEFFREY W , GHAYUR TARIQ
Abstract: The present invention encompasses IL-18 binding proteins, particularly antibodies that bind human interleukin-18 (hIL-18). Specifically, the invention relates to antibodies that are entirely human antibodies. Preferred antibodies have high affinity for hIL-18 and/or that neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.
-
130.
公开(公告)号:NZ523080A
公开(公告)日:2004-11-26
申请号:NZ52308001
申请日:2001-06-28
Applicant: ABBOTT LAB
Inventor: COLLINSON ALBERT , GHAYUR TARIQ , AVGERINOS GEORGE , DIXON RICHARD , KAYMAKCALAN ZEHRA
IPC: G01N33/50 , A61K39/395 , A61K47/48 , A61K49/00 , A61P1/04 , A61P17/06 , A61P25/00 , A61P29/00 , A61P37/06 , C07K16/24 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09 , C12N15/13 , C12P21/08 , G01N33/15 , G01N33/53 , G01N33/68 , G01N33/577 , A61K51/10 , C12N15/63
Abstract: A dual-specificity antibody or antigen-binding portion thereof specifically binds interleukin-1alpha and interleukin-1beta wherein the antibody is not a fully mouse antibody. The antibody can be used in diagnostic methods for detecting IL-á or IL-â and in the manufacture of a medicament for treating interlauikin-1-related disorders such as inflammatory disorder, autoimmune disorder i.e. rheumatoid arthritis, Crohn's disease, multiple sclerosis, insulin dependant diabetes mellitus and psoriasis. Methods of obtaining dual-specificity antibodies and methods of making an antibody are also described.
-
-
-
-
-
-
-
-
-